CD274 and urothelial carcinoma: In pretreated patients, ramucirumab in combination with pembrolizumab was associated with promising survival and prolonged PFS for patients with PD-L1-positive tumors (per an investigational version of the 22C3 assay) compared with patients with PD-L1-negative tumors in G/GEJ cancer, non-small-cell lung cancer, or urothelial carcinoma [26].